Meguro-ku, Japan
Meguro-ku, Japan

Time filter

Source Type

TOKYO--(BUSINESS WIRE)--PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a Technology License Agreement with Osaka-based Shionogi & Co., Ltd (“Shionogi”)(TOKYO:4507), to nonexclusively license PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, additional technology access payments, and is eligible to receive payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the PDPS technology. In addition, PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology. Similar to the previous 4 technology license agreements, work on peptide-drug conjugates (PDCs) is not included in the non-exclusive license. PeptiDream will continue to work with Shionogi to identify macrocyclic/constrained peptides against multiple targets of interest selected by Shionogi, and to optimize hit peptides into therapeutic peptides or small molecule products using PeptiDream’s PDPS technology, under the original agreement in February 2016. [Comment from Kiichi Kubota, CEO of PeptiDream] “We are delighted to announce the technology license with Shionogi. Our R&D collaboration with Shionogi, which started in February 2016, has already made incredible progress, with the first milestone already reached in March 2017, and now Shionogi becomes the first Japanese company to in-license our PDPS technology. Our proprietary PDPS technology is extremely effective at identifying hit candidates against almost any therapeutic target, even targets against which conventional methods have previously been unsuccessful. We continue to gain experience and knowledge in turning PDPS identified constrained peptide hit candidates into peptide therapeutics and/or small molecule therapeutics, efforts that are greatly accelerated with the information shared and learned across all our collaboration partners and programs. We strongly hope that this technology license will serve to accelerate the discovery and development efforts at Shionogi, ultimately leading to the identification of novel first-in-class and best-in-class therapeutics to address the world’s unmet medical needs. This technology license is now our 5th and shows that our PDPS technology is becoming a must-have platform for drug discovery worldwide.” In the past seven years, PeptiDream has established funded discovery collaborations with 17 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, and Janssen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, Lilly, Genentech, and Shionogi.


Patent
University of Tokyo and Peptidream Inc. | Date: 2014-08-04

An object of the present invention is to provide a method of producing a peptide containing a charged non-proteinogenic amino acid in a cell-free translation system, and the like. The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one tRNA to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the tRNA; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide.


Patent
University of Tokyo and PeptiDream Inc. | Date: 2016-06-15

An object of the present invention is to provide a method of producing a peptide containing a charged non-proteinogenic amino acid in a cell-free translation system, and the like. The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one tRNA to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the tRNA; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide.


Patent
University of Tokyo and Peptidream Inc. | Date: 2013-09-02

An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost. The present invention provides a peptide having the following amino acid sequence: [wherein, Xaa_(2 )represents Val or derivative thereof, Xaa_(6 )represents Asp or derivative thereof, Xaa_(7 )represents Pro or derivative thereof, Xaa_(8 )represents Trp or derivative thereof, Xaa_(10 )represents Asn or derivative thereof, Xaa_(11 )represents Gly or derivative thereof, Xaa_(12 )represents Leu or derivative thereof, Xaa_(1), Xaa_(3 )to Xaa_(5), Xaa_(9), and Xaa_(13 )to Xaa_(15 )each independently represent an arbitrary amino acid or derivative thereof]; or [wherein, Xaa_(24 )represents His or derivative thereof, Xaa_(25 )represents Pro or derivative thereof, and Xaa_(16 )to Xaa_(23 )and Xaa_(26 )to Xaa_(30 )each represent an arbitrary amino acid].


Patent
University of Tokyo and Peptidream Inc. | Date: 2014-05-12

An object of the present invention is to provide a method for producing a peptide library capable of incorporating an arbitrary number of arbitrary proteinogenic and/or non-proteinogenic amino acids in an arbitrary site. The invention provides a method for producing a peptide library including 110^(6 )or more kinds of peptides containing amino acids encoded by N_(1)N_(2)N_(3), including a step of preparing an mRNA library including mRNAs which encode peptides of the peptide library and each contain at least one N_(1)N_(2)N_(3); and a step of translating each mRNA of the mRNA library in a cell-free translation system added with tRNA containing an anticodon to any one of N_(1)N_(2)N_(3 )codons and charged with an amino acid corresponding to the codon (wherein, N_(1), N_(2), and N_(3 )are each independently selected from adenine (A), guanine (G), cytosine (C), and uracil (U) and an arbitrary amino acid is reassigned to each N_(1)N_(2)N_(3)).


Patent
University of Tokyo and PeptiDream Inc. | Date: 2016-03-16

An object of the present invention is to provide a method for producing a peptide library capable of incorporating an arbitrary number of arbitrary proteinogenic and/or non-proteinogenic amino acids in an arbitrary site. The invention provides a method for producing a peptide library including 110^(6) or more kinds of peptides containing amino acids encoded by N_(1)N_(2)N_(3), including a step of preparing an mRNA library including mRNAs which encode peptides of the peptide library and each contain at least one N_(1)N_(2)N_(3); and a step of translating each mRNA of the mRNA library in a cell-free translation system added with tRNA containing an anticodon to any one of N_(1)N_(2)N_(3) codons and charged with an amino acid corresponding to the codon (wherein, N_(1), N_(2), and N_(3) are each independently selected from adenine (A), guanine (G), cytosine (C), and uracil (U) and an arbitrary amino acid is reassigned to each N_(1)N_(2)N_(3)).


Patent
University of Tokyo and PeptiDream Inc. | Date: 2015-07-15

An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost. The present invention provides a peptide having the following amino acid sequence:_(2) represents Val or derivative thereof, Xaa_(6) represents Asp or derivative thereof, Xaa_(7) represents Pro or derivative thereof, Xaa_(8) represents Trp or derivative thereof, Xaa_(10) represents Asn or derivative thereof, Xaa_(11) represents Gly or derivative thereof, Xaa_(12) represents Leu or derivative thereof, Xaa_(1), Xaa_(3) to Xaa_(5), Xaa_(9), and Xaa_(13) to Xaa_(15) each independently represent an arbitrary amino acid or derivative thereof]; or_(24) represents His or derivative thereof, Xaa_(25) represents Pro or derivative thereof, and Xaa_(16) to Xaa_(23) and Xaa_(26) to Xaa_(30) each represent an arbitrary amino acid].


Patent
PeptiDream Inc. | Date: 2012-08-29

Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA] - [linker] - [peptide] conjugates assembled via such linkers.


Patent
PeptiDream Inc. | Date: 2015-12-09

An improved method used in selecting a useful protein, peptide, peptide analog by an evolution molecule engineering is provided. A transcription-linker association-translation coupling reaction system characterized by incorporation of a template DNA library to enable a step of forming translation product/linker/mRNA complexes through transcription of a template DNA library to mRNAs, association of mRNAs with linkers, translation of mRNAs, and binding with translation products to be automatically performed in a reaction system, comprising factors necessary for transcription, factors necessary for translation, and linkers.


Patent
Peptidream Inc. | Date: 2014-01-29

An improved method used in selecting a useful protein, peptide, peptide analog by an evolution molecule engineering is provided. A transcription-linker association-translation coupling reaction system characterized by incorporation of a template DNA library to enable a step of forming translation product/linker/mRNA complexes through transcription of a template DNA library to mRNAs, association of mRNAs with linkers, translation of mRNAs, and binding with translation products to be automatically performed in a reaction system, comprising factors necessary for transcription, factors necessary for translation, and linkers.

Loading PeptiDream Inc. collaborators
Loading PeptiDream Inc. collaborators